Endothelial dysfunction in a rat model of PCOS: Evidence of increased vasoconstrictor prostanoid activity

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4927-4936

  Keller, Jennifer ^a   Mandala, Maurizio ^a,b   Casson, Peter ^a   Osol, George ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLCHOLINE; ANDROSTANOLONE; COLLAGEN; ELASTIN; ESTRADIOL; FORMALDEHYDE; GLUCOSE; INDOMETACIN; INSULIN; NITRIC OXIDE SYNTHASE; PLACEBO; PROGESTERONE; PROSTAGLANDIN SYNTHASE; PROSTANOID; STEROID; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOGRAPHY; ARTERY COMPLIANCE; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL DIAMETER; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ESTRADIOL BLOOD LEVEL; ESTRUS CYCLE; FEMALE; GLUCOSE BLOOD LEVEL; HYPERANDROGENISM; INSULIN BLOOD LEVEL; MESENTERIC ARTERY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RADIOIMMUNOASSAY; RAT; SPLANCHNIC NERVE; STEROID BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; VASOCONSTRICTION; VASODILATATION; WEIGHT GAIN;

ACETYLCHOLINE; ANIMALS; DIHYDROTESTOSTERONE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; POLYCYSTIC OVARY SYNDROME; PROSTAGLANDINS; RATS; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 82355188209     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1424     Document Type: Article

References (53)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749 (Pubitemid 38766360)
2. Hopkinson ZE, Sattar N, Fleming R, Greer IA 1998 Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 317:329-332 (Pubitemid 28353831)
3. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA 1998 Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51:415-422 (Pubitemid 28223308)
4. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA 2010 Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95:2038-2049
5. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600 (Pubitemid 30337085)
6. Grundy SM, Brewer H}B Jr, Cleeman JI, Smith Jr SC, Lenfant C 2004 Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13-e18
7. Vanhoutte PM 2009 Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 73:595-601
8. Verma S, Buchanan MR, Anderson TJ 2003 Endothelial function testing as a biomarker of vascular disease. Circulation 108:2054-2059 (Pubitemid 37337577)
9. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592-5596 (Pubitemid 39518445)
10. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ 2005 Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90:4630-4635 (Pubitemid 41159353)
11. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA 2006 Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119:356 e351-e356
12. Dokras A, Jagasia DH, Maifeld M, Sinkey CA, VanVoorhis BJ, Haynes WG 2006 Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertil Steril 86:1702-1709
13. Hudecova M, Holte J, Olovsson M, Lind L, Poromaa IS 2010 Endothelial function in patients with polycystic ovary syndrome: a long-term follow-up study. Fertil Steril 94:2654-2658
14. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD 1996 Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610
15. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK 2005 Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:5088-5095 (Pubitemid 41262259)
16. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD 2001 Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415 (Pubitemid 32220633)
17. Sorensen MB, Franks S, Robertson C, Pennell DJ, Collins P 2006 Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin Endocrinol (Oxf) 65:655-659 (Pubitemid 44583828)
18. Furchgott RF, Vanhoutte PM 1989 Endothelium-derived relaxing and contracting factors. FASEB J 3:2007-2018 (Pubitemid 19187609)
19. Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P 2008 Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. Cardiovasc Res 79:179-186 (Pubitemid 351881935)
20. Qiao X, McConnell KR, Khalil RA 2008 Sex steroids and vascular responses in hypertension and aging. Gend Med 5(Suppl A):S46-S64 (Pubitemid 351455231)
21. Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD 2000 Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101:2040-2046 (Pubitemid 30233166)
22. Mannerås L, Cajander S, Holmäng A, Seleskovic Z, Lystig T, Lönn M, Stener-Victorin E 2007 A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 148:3781-3791 (Pubitemid 47105840)
23. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W 2003 Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2760-2766 (Pubitemid 36724453)
24. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE 2003 Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 88:4682-4688 (Pubitemid 37357512)
25. Goebelsmann U, Arce JJ, Thorneycroft IH, Mishell Jr DR 1974 Serum testosterone concentrations in women throughout the menstrual cycle and following HCG administration. Am J Obstet Gynecol 119:445-452
26. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE 1999 Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165-173 (Pubitemid 29260048)
27. Serafini P, Lobo RA 1985 Increased 5α-reductase activity in idiopathic hirsutism. Fertil Steril 43:74-78 (Pubitemid 15198278)
28. Goebelsmann U, Bernstein G, Gale J, Kletzky O, Nakamura R, Coulson A, Korelitz J 1979 Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. New York: Academic Press
29. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP 2008 Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab 295:E1269-E1276
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
31. Halpern W, Osol G, Coy GS 1984 Mechanical behavior of pressurized in vitro prearteriolar vessels determined with a video system. Ann Biomed Eng 12:463-479 (Pubitemid 15149742)
32. Freeman M, (Ed.).1994 The neuroendocrine control of the ovarian cycle of the rat. 2nd ed. New York: Raven Press
33. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB 1998 Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847 (Pubitemid 28213628)
34. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A 1999 Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 23:936-942 (Pubitemid 29423936)
35. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S 2001 Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 88:1264-1269 (Pubitemid 33132095)
36. Furchgott RF, Zawadzki JV 1980 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376 (Pubitemid 11169009)
37. Félétou M, Huang Y, Vanhoutte PM 2010 Vasoconstrictor prostanoids. Pflugers Arch 459:941-950
38. Coleman RA, Smith WL, Narumiya S 1994 International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229 (Pubitemid 24185151)
39. Chenevard R, Hürlimann D, Béchir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Lüscher TF, Noll G, Ruschitzka F 2003 SelectiveCOX-2inhibition improves endothelial function in coronary artery disease. Circulation 107:405-409
40. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney Jr JF, Morrow JD, Vita JA 2003 Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42:310-315 (Pubitemid 37093478)
41. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S 2003 Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41:1198-1204 (Pubitemid 36384909)
42. Lesault PF, Boyer L, Pelle G, Covali-Noroc A, Rideau D, Akakpo S, Teiger E, Dubois-Randé JL, Adnot S 2011 Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br J Clin Pharmacol 71:844-851
43. Gelosa P, Sevin G, Pignieri A, Budelli S, Castiglioni L, Blanc-Guillemaud V, Lerond L, Tremoli E, Sironi L 2011 Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 300:H762-h768
44. Lakhani K, Yang W, Dooley A, El-Mahdi E, Sundaresan M, McLellan S, Bruckdorfer R, Leonard A, Seifalian A, Hardiman P 2006 Aortic function is compromised in a rat model of polycystic ovary syndrome. Hum Reprod 21:651-656 (Pubitemid 43372969)
45. Mahajan DK 1988 Polycystic ovarian disease: animal models. Endocrinol Metab Clin North Am 17:705-732 (Pubitemid 19005974)
46. Alexanderson C, Stener-Victorin E, Kullberg J, Nilsson S, Levin M, Cajander S, Lönn L, Lönn M, Holmäng A 2010 A single early postnatal estradiol injection affects morphology and gene expression of the ovary and parametrial adipose tissue in adult female rats. J Steroid Biochem Mol Biol 122:82-90
47. Kafali H, Iriadam M, Ozardali I, Demir N 2004 Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 35:103-108 (Pubitemid 38316828)
48. Ovalle F, Azziz R 2002 Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095-1105 (Pubitemid 34626313)
49. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA 1992 Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 167:1807-1812 (Pubitemid 23009328)
50. Talbott EO, Zborowskii JV, Boudraux MY 2004 Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 56:27-39 (Pubitemid 38313779)
51. Fritz MA, Speroff L 2011 Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams, Wilkins
52. Orio Jr F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A 2004 Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588-4593 (Pubitemid 39244474)
53. Wassmann K, Wassmann S, Nickenig G 2005 Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 97:1046-1054 (Pubitemid 41668918)